Aurora kinase inhibitors: Progress towards the clinic

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33139272" target="_blank" >RIV/61989592:15110/12:33139272 - isvavai.cz</a>

Alternative codes found

RIV/61388963:_____/12:00377543

Result on the web

<a href="http://dx.doi.org/10.1007/s10637-012-9798-6" target="_blank" >http://dx.doi.org/10.1007/s10637-012-9798-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10637-012-9798-6" target="_blank" >10.1007/s10637-012-9798-6</a>

Result language

angličtina

Original language name

Aurora kinase inhibitors: Progress towards the clinic

Original language description

The Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation in Drosophila melanogaster. They soon became the focus of much attention because of their importance inhuman biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered, and are currently under development. The binding modes of Aurora kinase inhibitors to Aurora kinases share specific hydrogen bonds between the inhibitor core and the back bone of the kinase hinge region, while others parts of the molecules may point to different parts of the active site via noncovalent interactions. Currently there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and stat

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Investigational new drugs

ISSN

0167-6997

e-ISSN

—

Volume of the periodical

30

Issue of the periodical within the volume

6

Country of publishing house

US - UNITED STATES

Number of pages

22

Pages from-to

2411-2432

UT code for WoS article

—

EID of the result in the Scopus database

—